TOKYO, March 22, 2022 — FUJIFILM Corporation (President and CEO, Representative Director: Teiichi Goto) has announced an amendment of certain part of the share transfer agreement with PeptiDream Inc. (PeptiDream) in relation to the radiopharmaceutical business of FUJIFILM Toyama Chemical Co., Ltd. (FUJIFILM Toyama Chemical). Under the amendment, a lump sum payment from PeptiDream will become 22.1 billion yen, changed from previously announced 30.5 billion yen, given the return of domestic marketing rights*1 of Lutathera® Injection to Advanced Accelerator Applications International S.A. (AAA), a Novartis company. Fujifilm will receive the transfer fee from AAA in exchange for such return.
On September 2, 2021, Fujifilm has entered into a share transfer agreement with PeptiDream, under which all outstanding shares of the newly established company (the new radiopharmaceutical company), to which FUJIFILM Toyama Chemical’s radiopharmaceutical business is succeeded, will be transferred to PeptiDream. In the course of preparation for the transfer of shares, Fujifilm had discussions on domestic promotion of Lutathera with AAA (developer of Lutathera), PeptiDream and other related parties and, as a result of such discussions, it has been agreed that domestic marketing rights which currently FUJIFILM Toyama Chemical holds will be returned to AAA.
Fujifilm plans to complete the share transfer of the new radiopharmaceutical company to PeptiDream on March 28, 2022. The newly established company will be named “PDR Pharma Co., Ltd.” and operate its business as an affiliate of PeptiDream.
FUJIFILM Holdings Corporation
Corporate Communications Division
Public Relations Group